637 related articles for article (PubMed ID: 15958610)
1. Elevated expression of Wnt antagonists is a common event in hepatoblastomas.
Koch A; Waha A; Hartmann W; Hrychyk A; Schüller U; Waha A; Wharton KA; Fuchs SY; von Schweinitz D; Pietsch T
Clin Cancer Res; 2005 Jun; 11(12):4295-304. PubMed ID: 15958610
[TBL] [Abstract][Full Text] [Related]
2. Mutations and elevated transcriptional activity of conductin (AXIN2) in hepatoblastomas.
Koch A; Weber N; Waha A; Hartmann W; Denkhaus D; Behrens J; Birchmeier W; von Schweinitz D; Pietsch T
J Pathol; 2004 Dec; 204(5):546-54. PubMed ID: 15538750
[TBL] [Abstract][Full Text] [Related]
3. Elevated protein expression of cyclin D1 and Fra-1 but decreased expression of c-Myc in human colorectal adenocarcinomas overexpressing beta-catenin.
Wang HL; Wang J; Xiao SY; Haydon R; Stoiber D; He TC; Bissonnette M; Hart J
Int J Cancer; 2002 Oct; 101(4):301-10. PubMed ID: 12209953
[TBL] [Abstract][Full Text] [Related]
4. Epigenetic inactivation of Wnt inhibitory factor-1 plays an important role in bladder cancer through aberrant canonical Wnt/beta-catenin signaling pathway.
Urakami S; Shiina H; Enokida H; Kawakami T; Tokizane T; Ogishima T; Tanaka Y; Li LC; Ribeiro-Filho LA; Terashima M; Kikuno N; Adachi H; Yoneda T; Kishi H; Shigeno K; Konety BR; Igawa M; Dahiya R
Clin Cancer Res; 2006 Jan; 12(2):383-91. PubMed ID: 16428476
[TBL] [Abstract][Full Text] [Related]
5. The human T-cell factor-4 gene splicing isoforms, Wnt signal pathway, and apoptosis in renal cell carcinoma.
Shiina H; Igawa M; Breault J; Ribeiro-Filho L; Pookot D; Urakami S; Terashima M; Deguchi M; Yamanaka M; Shirai M; Kaneuchi M; Kane CJ; Dahiya R
Clin Cancer Res; 2003 Jun; 9(6):2121-32. PubMed ID: 12796377
[TBL] [Abstract][Full Text] [Related]
6. Aberrant expression and function of TCF4 in the proliferation of hepatocellular carcinoma cell line BEL-7402.
Zhao DH; Hong JJ; Guo SY; Yang RL; Yuan J; Wen CY; Zhou KY; Li CJ
Cell Res; 2004 Feb; 14(1):74-80. PubMed ID: 15040893
[TBL] [Abstract][Full Text] [Related]
7. Expression of potential beta-catenin targets, cyclin D1, c-Jun, c-Myc, E-cadherin, and EGFR in chemically induced hepatocellular neoplasms from B6C3F1 mice.
Anna CH; Iida M; Sills RC; Devereux TR
Toxicol Appl Pharmacol; 2003 Jul; 190(2):135-45. PubMed ID: 12878043
[TBL] [Abstract][Full Text] [Related]
8. Mutations of the Wnt antagonist AXIN2 (Conductin) result in TCF-dependent transcription in medulloblastomas.
Koch A; Hrychyk A; Hartmann W; Waha A; Mikeska T; Waha A; Schüller U; Sörensen N; Berthold F; Goodyer CG; Wiestler OD; Birchmeier W; Behrens J; Pietsch T
Int J Cancer; 2007 Jul; 121(2):284-91. PubMed ID: 17373666
[TBL] [Abstract][Full Text] [Related]
9. Mutational spectrum of beta-catenin, AXIN1, and AXIN2 in hepatocellular carcinomas and hepatoblastomas.
Taniguchi K; Roberts LR; Aderca IN; Dong X; Qian C; Murphy LM; Nagorney DM; Burgart LJ; Roche PC; Smith DI; Ross JA; Liu W
Oncogene; 2002 Jul; 21(31):4863-71. PubMed ID: 12101426
[TBL] [Abstract][Full Text] [Related]
10. Activation of beta-catenin in epithelial and mesenchymal hepatoblastomas.
Wei Y; Fabre M; Branchereau S; Gauthier F; Perilongo G; Buendia MA
Oncogene; 2000 Jan; 19(4):498-504. PubMed ID: 10698519
[TBL] [Abstract][Full Text] [Related]
11. Wnt signaling in hepatocellular carcinoma: analysis of mutation and expression of beta-catenin, T-cell factor-4 and glycogen synthase kinase 3-beta genes.
Cui J; Zhou X; Liu Y; Tang Z; Romeih M
J Gastroenterol Hepatol; 2003 Mar; 18(3):280-7. PubMed ID: 12603528
[TBL] [Abstract][Full Text] [Related]
12. beta-Catenin and met deregulation in childhood Hepatoblastomas.
Ranganathan S; Tan X; Monga SP
Pediatr Dev Pathol; 2005; 8(4):435-47. PubMed ID: 16211454
[TBL] [Abstract][Full Text] [Related]
13. Histologic subtypes of hepatoblastoma are characterized by differential canonical Wnt and Notch pathway activation in DLK+ precursors.
López-Terrada D; Gunaratne PH; Adesina AM; Pulliam J; Hoang DM; Nguyen Y; Mistretta TA; Margolin J; Finegold MJ
Hum Pathol; 2009 Jun; 40(6):783-94. PubMed ID: 19200579
[TBL] [Abstract][Full Text] [Related]
14. Beta-catenin mutations and protein accumulation in all hepatoblastomas examined from B6C3F1 mice treated with anthraquinone or oxazepam.
Anna CH; Sills RC; Foley JF; Stockton PS; Ton TV; Devereux TR
Cancer Res; 2000 Jun; 60(11):2864-8. PubMed ID: 10850429
[TBL] [Abstract][Full Text] [Related]
15. Overexpression of human Dickkopf-1, an antagonist of wingless/WNT signaling, in human hepatoblastomas and Wilms' tumors.
Wirths O; Waha A; Weggen S; Schirmacher P; Kühne T; Goodyer CG; Albrecht S; Von Schweinitz D; Pietsch T
Lab Invest; 2003 Mar; 83(3):429-34. PubMed ID: 12649343
[TBL] [Abstract][Full Text] [Related]
16. Childhood hepatoblastomas frequently carry a mutated degradation targeting box of the beta-catenin gene.
Koch A; Denkhaus D; Albrecht S; Leuschner I; von Schweinitz D; Pietsch T
Cancer Res; 1999 Jan; 59(2):269-73. PubMed ID: 9927029
[TBL] [Abstract][Full Text] [Related]
17. Redundant expression of canonical Wnt ligands in human breast cancer cell lines.
Benhaj K; Akcali KC; Ozturk M
Oncol Rep; 2006 Mar; 15(3):701-7. PubMed ID: 16465433
[TBL] [Abstract][Full Text] [Related]
18. Cross-talk between Rac1 GTPase and dysregulated Wnt signaling pathway leads to cellular redistribution of beta-catenin and TCF/LEF-mediated transcriptional activation.
Esufali S; Bapat B
Oncogene; 2004 Oct; 23(50):8260-71. PubMed ID: 15377999
[TBL] [Abstract][Full Text] [Related]
19. Alterations of beta-catenin and Tcf-4 instead of GSK-3beta contribute to activation of Wnt pathway in hepatocellular carcinoma.
Cui J; Zhou X; Liu Y; Tang Z; Romeih M
Chin Med J (Engl); 2003 Dec; 116(12):1885-92. PubMed ID: 14687479
[TBL] [Abstract][Full Text] [Related]
20. Overview of the molecular biology of hepatocellular neoplasms and hepatoblastomas of the mouse liver.
Kim Y; Sills RC; Houle CD
Toxicol Pathol; 2005; 33(1):175-80. PubMed ID: 15805069
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
